Sign up USA
Proactive Investors - Run By Investors For Investors

GTx reveals pre-clinical success for potential SUI treatment

GTx showed it could increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation.
GTx reveals pre-clinical success for potential SUI treatment
GTx is evaluating an orally administered treatment for postmenopausal women

GTx Inc (NASDAQ:GTXI) has told investors it has shown that its technology can increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation.

A Phase 2 proof-of-concept clinical trial is currently being conducted for postmenopausal women with stress urinary incontinence (SUI), though today’s data is from a preclinical study, modelled using animals.

This study approximates the pelvic floor changes that can be associated with SUI, the company said.

Two of the company’s elective androgen receptor modulators (SARMs) - GTx-024 (enobosarm) and GTx-027 - were used in the study in a mouse model.

“These results demonstrate the ability of these SARMs to restore the pelvic floor muscles to their normal weight and provide support for a potential role of these compounds in the treatment of SUI,” said Dr Ramesh Narayanan, who is acting as consultant to GTx.

The result is being presented today in New Orleans, at a meeting of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU).

In its ongoing Phase 2 trial, GTx is evaluating the effects of orally administered enobosarm.

Jamie_55a91591db06b.jpg


Register here to be notified of future GTXI Company articles
View full GTXI profile

GTx Timeline

Related Articles

GW_Pharma.png
November 22 2016
With the balance sheet now significantly strengthened, we anticipate the company is well-positioned to capture value in areas where its technology platforms offer material improvements for patient care - Panmure Gordon.
picture of drug lab
November 07 2016
The aim is for clinical trials for AP102 to start next year
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC